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Purpose: Exertional thrombosis of the axillary and subclavian veins, also known as 
Paget-Schr6tter syndrome, has been increasingly recognized in recent years as a cause of 
long-term orbidity. Recent aggressive approaches totreating Paget-Schr6tter syndrome 
have suggested the association of early failure with residual subclavian vein stenosis. As a 
result, the use of endolmninal stents has been proposed as an aid to venous percutaneous 
transluminal ngioplasty for this disorder. 
Methods: This report outlines the therapy of 11 consecutive patients with Paget-Schr6tter 
syndrome who were treated at our institution between October, 1992, and December, 
1995. Stents were placed when percutaneous transluminal ngioplasty was unsuccessfitl at
achieving an adequate residual lumen. 
Results: Stents were placed after initial thrombolysis n six patients and in late follow-up 
in two patients. Of the six patients who had stents placed at initial thrombolysis, first-rib 
resection was eventually performed in four. In two patients first-rib resection was not 
performed, and stent fracture occurred in both. Late patency was achieved in the stents of 
six of the eight patients. 
Conclusions: Trials to evaluate stents as an adjunct o conventional therapy seem war- 
ranted. The use of stents alone without first-rib resection, however, appears to be 
associated with stent fracture. (J Vasc Surg 1996;24:974-83.) 
Since the initial descriptions ofaxillary-subclavian 
vein thrombosis more than 100 years ago, the man- 
agement of this entity has been linked to the current 
therapies in vogue for systemic vascular diseases. 
Therefore, it is only fitting that in this era of  coronary 
and peripheral arterial stent placement that the tech- 
nique of venous stent placement be explored for 
Paget-Schr6tter syndrome. The addition of stents to 
the management of Paget-Schr6tter syndrome is a 
natural evolution of the protocol proposed by 
Machleder. 1 Nonetheless, the role, timing, and com- 
plications of venous stents in this disorder remain to 
be defined. 
Stents for vascular treatment first became avail- 
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ble about 1985. Currently, there a three main 
types of stent in use: the Palmaz stent (Johnson 8: 
Johnson Interventional Systems Co., Warren, N.J.), 
the Wallstent (Schneider, Minneapolis, Minn.), and 
the Gianturco stent (Cook, Bloomington, Ind.). 
Palmaz stents are rigid stents that are balloon-ex- 
panded to provide expansile force against he vessel 
wall. On the other hand, both Wallstents and Gian- 
-turco stents are self-expanding. The inherent mem- 
ory within the wire will determine the expansile force 
that resists compression and imparts resiliency. The 
Wallstent is a mesh of  wires that can be compressed to
a very low profile for introduction. Giannlrco stents 
tend to have larger introducer sizes, although they are 
currently also available in large diameters, making 
them potentially better for central vessels. Given the 
motion of  the arm and shoulder at the thoracic inlet, 
a flexible self-expanding stent would seem to be the 
best option for venous tents in Paget-Schr0tter syn- 
drome. 
The pathophysiologic mechanism of the Paget- 
Schr6tter syndrome implicates compression of the 
subclavian vein between the first rib and the clavicle. 
In addition, abnormal soft tissue, muscles, or bands 
of  fascia may also be present, much as in the neuro- 
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Fig. 1. Initial diagnostic venogram of left arm in i itial patient, a17-year-old woman with le~ 
arm pain and swelling of several days duration. Subclavian vein is acutely thrombosed, with 
extensive collateral formation to jugular system. 
genic form of thoracic outlet syndrome. 2 Therefore, 
physical compression forces in the thoracic inlet may 
interfere with the function of  stents in this location. 
The longevity of a stent subjected to these forces 
could be a significant concern. For example, com- 
pression of Palmaz stents in this location have been 
previously documented.3 
Generally, the management of Paget-Schr6tter 
syndrome is as outlined in Table I. The arrowheads 
represent the times within the management scheme 
where venous stent placement might occur. As dia- 
grammed, there are three points in time at which 
venous stent placement might be considered in 
Paget-Schrttter syndrome, all of which are associated 
with routine venographic scans. First, after the initial 
venographic scan and thrombolysis, ignificant severe 
residual stenosis may be present; if this stenosis 
flow-restricting, then percutaneous transluminal bal- 
loon angioplasty (PTA) may be needed at this point 
to prevent rethrombosis. I f PTA is unsuccessful at 
eliminating the flow restriction, then venous stent 
placement may be warranted. The second time point 
at which venou s stent placement may be undertaken 
is at the initial follow-up venographic scan, after 
first-rib resection. This is the normal time that venous 
PTA is performed for residual stenosis and therefore 
may also be an appropriate time for venous stent 
Table I. Modified management protocol for 
Paget-Schrttter svndrome (after Machleder 1 
• Venographic diagnosis 
• Intravenous, catheter directed) thrombolytic therapy 
1~ Possible PTA +_ venous tent placement 
• Systemic anncoagulation for 3 months 
• First-rib resection for residual compression 
• PTA for residual stenosis 
Possible venous tent placement 
• Venographic follow-up studies 
Possible PTA -+ venous tem placement 
placement. Finally, recurrent stenosis may occur at 
any time point after treatment, and repeat PTA or 
venous stent placement may be needed. 
Given these complicated issues concerning the 
use of venous tents in Paget-Schrttter syndrome, we 
undertook to review our recent experience. 
MATERIALS AND METHODS 
This retrospective case review represents the last 
11 patients who had Paget-Schrttter syndrome and 
were treated at the Yale-New Haven Hospital be- 
tween October, 1992. and December, 1995. These 
patients were chosen for review, beginning with the 
initial patient who was treated with a venous tent for 
Paget-SchrOtter syndrome and continuing to the 
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Fig. 2. In the same patient, after 22 hours ofurokinase infusion, digital subtraction venogram 
demonstrates patent subclavian vein with significant residual obstruction. 
Table I I .  Patient data 
Patient Date of Date stent Date first Clinical Venographic 
no. thrombolysis placed rib resected outcome outcome 
1 10/13/92 10/14/92  Refused Good 
2 10/28/92 None 11/22/92 Good 
3 2 /1 /93  2 /1 /93  Refused Good 
4 6 /21 /93  6 /22 /93  6/29/93 Good 
5 10/20/93 10/20/93 12/29/93 Good 
6 6/28/94 3/1/95 9/20/94 Good 
7 7/11/94 7/12/94 8/12/94 Good 
8 1/3/95 None Not offered Died (pancreatic 
adenocarcinoma) 
9 2/6/95 2/7/95 Not offered Poor 
10 6/13/94 6/14/94 Not offered Poor 
11 6/21/95 None Refused Fair 
Patent, stent fractured 
Patent 
Patent, stcnt fractured 
Patent, second rib 
compression 
Patent 
Patent 
Patent 
Rethrombosed 
Rethrombosed 
Rethrombosed 
Restenosis 
present, allowing an adequate follow-up interval for 
observation of outcomes. Retrospective chart review 
documented the history of the thrombosis, the pres- 
ence of  symptoms, and the treatments that were 
performed. 
Voluntary follow-up by a venographic scan was 
offered at 6- to 12-month intervals. Venographic 
scans were performed with both digital subtraction 
and cut-film techniques and low osmolar contrast. 
The general treatment protocols were a modification 
of  the protocol reported by Machleder. ~Thrombol- 
ysis was performed with urokinase in all cases; treat- 
ment was initiated with a bolus of 250,000 to 
500,000 U into the clot, followed by infusion of  
60,000 to 180,000 U/hour .  Thrombolysis duration 
and timing were dictated by the interventional radi- 
ologist and the vascular surgeon. Venous stents were 
used at the discretion of these individuals, as well. All 
patients with venous stents had Wallstents placed, 
which ranged in diameter from 10 mm to 14 mm. 
The length ofstents placed was determined by adding 
approximately 2 cm to the apparent length of the 
lesion. In all patients in whom stents were placed, at 
least a 50% residual stenosis remained after PTA 
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Fig. 3. PTA of residual stenosis (with a 10 mm by 5 cm balloon inflated to 5 atmospheres) 
demonsn'ates persistent waist at stenosis that never completely dilated (paired arrows). Subse- 
quently, 70% residual narrowing was present. 
alone. Two groups were defined for stent placement: 
at the time of  diagnosis and initial thrombolysis 
(group I); and at late venographic follow-up, in pa- 
tients who underwent first-rib resection and those 
who did not (group I IL 
All patients were given heparin after thrombob ~-
sis, independent of whether a stent was placed First- 
rib resection was offered at the discretion of the 
individual vascular surgeon. The timing of this pro- 
cedure was also at the discretion of the surgeon and 
patient. Warfarin was used in all patients as outlined 
previously. 1 
RESULTS 
Eleven panents were treated as outlined above; six 
were women and five were men. The average age of 
these patients was 30.4 years (range, 17 to 5I  yearsL 
None of  these patients had a history of deep venous 
thrombosis or a family history of thrombosis. Four 
patients (36%) had thrombosis associated with exer- 
tion or trauma. The remainder had no associated 
event. Thrombosis occurred in the dominant extrem- 
ity in only five patients (45%), in contrast to previous 
reports. 1,46 No patients had evidence of significant 
neurologic symptoms at initial presentation. All pa- 
tients had discomfort and edema in the involved 
extremity that grew worse with exeruon. 
The diagnosis was confirmed by a venographic 
scan in all cases (Fig. 1). Partial thrombosis was 
present at the time of diagnosis in only one patient. 
Duplex ultrasound scans were used as a screening 
method before the venographic scan in five patients, 
and was predictive of  thrombosis in all five. ALl eleven 
patients underwent attempted thrombolysis after ini- 
tial venographic diagnosis (Table II). In addition to 
the subclavian vein, the axillary veto was thrombosed 
on the venographic scan in seven patients (63%) and 
the brachial vein in six (54%). Stress abduction veno- 
graphic scans after thrombolysis documented in- 
creased venous compression on the involved side in 
all panents and on the contralateral side in all but one 
patient. PTA was used when residual stenosis was at 
least 50% after thrombotysis (Figs. 2 and 3 h Veno- 
graphic results after stent placement were generally 
excellent (Fig. 4). Stent deformation was seen in all 
patients with the first rib in situ under stress abduc- 
tion venography. Only one of the four patients who 
had first-rib resection had deformation of the srent 
under stress, which resulted from compression at the 
level of  the second rib and was confirmed by a mag- 
netic resonance angiographic scan. 
First-rib resection was offered to eight patients, 
and three refused. Stents were used in all three pa- 
tients who refused first-rib resection, two as the initial 
treatment and one in an attempt at late salvage. The 
two early stents that were placed without first-rib 
resection both fractured in follow-up within 8 
months (Figs. 5 and 63. Nonetheless, both subclavian 
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Fig. 4. Completion venogram after PTA and venous tent placement using a 12 mm by 9 cm 
Wallstent. 
veins remain patent, although with some stenosis, at 
11 and 30 months after stent placement alone. The 
late stent placed for salvage failed, resulting in recur- 
rent subclavian and axillary vein thrombosis. One 
additional stent fractured after first-rib resection in a 
patient who had residual compression of the vein by 
the second rib. 
First-rib resection was performed at the time of 
the initial admission in two patients and in early 
follow-up in the remaining three. One additional 
patient is still awaiting first-rib resection, without use 
of PTA or a venous stent. Of the five patients who 
underwent first-rib resection, four had venous tents 
placed before first-fib removal. Of the eight venous 
stents placed, six were in group I (placed after initial 
thrombolysis and PTA). Stenoses developed in the 
two group II patients at 180 and 246 days after 
diagnosis and thrombolysis, the latter after first-rib 
resection and previous PTA of a late subclavian vein 
stenosis. 
Late follow-up confirmed absent or minimal 
symptoms in eight patients (72%). Lower extremity 
deep venous thrombosis subsequently developed in 
one of the remaining three patients; pancreatic carci- 
noma also was diagnosed in the patient, who died in 
follow-up. In two patients, initial follow-up veno- 
graphic scans at 8 to 12 weeks (before first-rib resec- 
tion) demonstrated poor subclavian flow and exten- 
sive collateral vessels resulting from early, extensive 
rethrombosis; collateral f ow remained unaffected un- 
der stress abduction venographic scans in both pa- 
tients. As a result, first-rib resection was believed to 
be of no benefit in these two patients and was not 
performed. Both  of these patients remain signifi- 
cantly symptomatic with limited activities. 
DISCUSSION 
The treatment of Paget-Schr6tter syndrome cen- 
ters on the maintenance of patency of the axillary- 
subclavian veins. As a result, a more aggressive focus 
on the restoration of normal anatomy has led to the 
extensive use ofthrombolyti c therapy, first-rib resec- 
tion, and balloon angioplasty for residual steno- 
sis. 1,7-1° In spite of this approach, many patients have 
significant residual stenosis of the subclavian vein 
after complete thrombolysis. Early recurrent throm- 
bosis, presumably as a result of this residual disease, is
the usual cause of treatment failure in these patients. 
Therefore, improving short-term outcomes by reliev- 
ing flow abnormalities within the subclavian vein 
would seem a logical solution to early rethrombosis. 
The natural history of Paget-Schrftter syndrome 
when treated with thrombolysis and anticoagulation 
therapy alone has not been defined. Nonetheless, it is 
generally agreed that the first rib contributes to the 
development of the venous thrombosis. Therefore, 
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Fig. 5. In this same patient at 8 months' follow-up, fracture of venous tent is demonstrated by
chest roentgenogram (arrow). 
the removal of  the first rib, although empiric based on 
currently available natural history data, seems logical 
in the management of venous thoracic outlet syn- 
drome. The rates of  recurrence of Paget-Schr6tter 
syndrome, both in patients with and patients without 
first-rib resection, remain to be determined. 
In an effort to improve the early subclavian vein 
patency, PTA of the subclavian vein was tried first in 
all our group I patients (after initial thrombolysis). 
This approach as been condemned in the past. TM 
with the best results for PTA in some series occurring 
after first-rib resection. However, significant residual 
stenosis after early PTA remains an issue32 This re- 
sidual lesion, refractory to balloon dilatation, usually 
represents fibrous scar within the subclavian vein as it 
passes over the first rib. This lesion often occurs just 
medial to the first rib from downstream propagation 
of the thrombus. Thus when stents became available 
for endoluminal use, their placement within the sub- 
clavian vein to treat residual stenosis became the next 
logical step. la,',4 
The choice of which stents to use in this area 
seems straightforward. In our experience, ven when 
the first rib is removed some patients exhibit residual 
stress compression of  the subclavian vein. Therefore, 
the use of  a rigid stent in this location seems ill- 
advised because the physical forces at the thoracic 
inlet would likely result in permanent deformity of 
the venous stent. We currently favor the use of the 
Wallstent because of its resilience, its widespread 
availability, and its appropriate sizes for subclavian 
veins. Although we have no experience with the 
Gianturco stent, it represents a possible alternative to 
the use of  the Wallstent. is The Patmaz stent, in our 
opinion, should not be used in the subclavian vein 
because of  the effect of  the deforming forces at tlae 
thoracic inlet on its rigid structure, a 
We recommend placement of these lumen-ex- 
panding stents for any residual stenosis >50% that 
remains after PTA; the stents should be used to aid 
expansion of the venous lumen. In all cases in which 
stents were used in this location, a >70% luminal 
diameter was achieved. 
In the two patients in whom a venous stent was 
placed without first-rib removal, stem fracture oc- 
curred in follow-up with resultant stenoses at the 
fracture site. It  appears that even the relatively flexible 
Wallstent cannot withstand the repetitive forces that 
are present at the thoracic outlet. Therefore, our 
recommendation is that the first rib be removed even 
when venous stents are placed. Currently, we restrict 
the actavity of our patients' involved extremities for 
the initial 3 months ofanticoagulation therapy before 
first-rib removal. An additional patient who had re- 
sidual stress compression over the second rib after 
first-rib resection also fractured his stent. The issue of  
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Fig. 6. Digital subtraction venogram in same patient at 30 months' follow-up demonstrates 
venous patency with fractured stent (arrow). Presence of collateral veins suggests hemodynam- 
ically significant restenosis. 
residual compression after first-rib removal remains 
unresolved; because this phenomenon is relatively 
rare in our experience, we do not currently recom- 
mend second rib removal. 
In two stent patients first-rib resection was not 
recommended because of  extensive rethrombosis n
follow-up, despite anticoagulation therapy. Both pa- 
tients remain significantly symptomatic in follow-up, 
although neither has documented stent fracture on 
relatively limited imaging follow-up. The presence of 
symptoms with arm activity in these patients may help 
to prevent overuse and early stent fracture. Nonethe- 
less, we expect hat stent fracture will occur in these 
patients at some point in follow-up. 
There is no evidence that stent placement in- 
creases the risk of rethrombosis. Even the two frac- 
tured stents remain patent in follow-up. Nonetheless, 
the long-term consequences of venous stent place- 
ment remain undefined. No long-term studies exist 
to define the biologic reaction to stents in the venous 
system over several years. These patients are often 
young, and the consequences of any adverse intimal 
reaction will be magnified by the long duration of 
USe. 
Although the timing of  first-rib resection has 
been controversial in the past, 1,16-19 we preferred to 
alter the timing of  first-rib resection to fit thc clinical 
need. In competitive athletes, for example, first-rib 
resection at initial diagnosis may shorten the rehabil- 
itation period, allowing earlier cessation of anticoag- 
ulation therapy and the resumption of  contact sports. 
Nonetheless, if there are no contraindications to
waiting for 8 to 12 weeks, this is our preferred timing 
for first-rib resection. 
In the majority of our patients, contralateral stress 
abduction compression of  the subclavian vein was 
present, as has previously been noted. 2° We believe 
that there is a predisposition to Paget-Schr6tter syn- 
drome on the basis of anatomic hanges at the tho- 
racic oudet. I f  this is true, then the development of
contralateral neurologic or vascular symptoms should 
be more likely in these patients. Longitudinal studies, 
however, are lacldng. In none of these patients has 
symptomatic contralateral venous disease nsued. In 
one patient, however, early neurologic symptoms 
consistent with thoracic outlet syndrome have devel- 
oped in the contralateral rm. 
CONCLUSION 
We believe that the use of stents for residual vein 
stenosis after PTA is an adjunct in the management of
Paget-Schr6tter syndrome. Venous stent placement 
alone does not seem to stabilize the thoracic outlet; in 
our opinion, subclavian vein stents for Paget-Schr6t- 
JOURNAL OF VASCULAR SURGERY 
Volume 24, Number 6 Meier et aL 981 
ter syndrome should always be accompanied by first- 
rib resection, unless precluded by significant re- 
thrombosis. On  the basis of our l imited but  positive 
experience, it would appear that a prospective trial is 
warranted to confirm the apparent benefit of  placing 
subclavian vein stents in two groups of patients with 
Paget-Schrttter syndrome: first, those who have se- 
vere residual stenosis in the subclavian vein after the 
initial thrombolysis but  before first-rib resection; and 
second, those who have late restenosis. Unt i l  such a 
trial is accomplished, we believe that the selective use 
of endoluminal  venous stents represents an advance 
in the management  of these challenging patients who 
have Paget-Schrttter syndrome. 
REFERENCES 
1. Machleder HI. Evaluation of a new treatment strategy for 
Paget-Schroetter syndrome: spontaneous thrombosis of the 
axillary-subctavian ei . J Vase Surg 1993;17:305-17. 
2. Thompson RW, Sclmeider PA, Nelken NA, Skioldebrand CG, 
Stoney RJ. Circumferential venolysis and paractavicular tho- 
racic outlet decompression for "effort thrombosis" of the 
subclavian vein. J Vase Surg 1992;16:723-32. 
3. Bjarnason H, Hunter DW, Crain MR, Ferral H, Miltz-Miller 
SE, Wegryn SA, Collapse of a Palrnaz stent in the subclavian 
vein. AJRAm J Roentgenol 1993;160:1123-4. 
4. Hughes ESR. Collective review. Venous obstruction i upper 
extremity (Paget-Schroetter's syndrome): review of 320 cases. 
International Abstracts of Surgery 1949;88:89-94. 
5. Adams JT, DeWeese JA: "Effort" thrombosis of the axillary 
and subclavian veins. J Trauma 1971;11:923-30. 
6. AbuRahma AF, Sadler DL, Robinson PA. Axillary-subdavian 
vein thrombosis: changing patterns of etiology, diagnostic, 
and therapeutic modalities. Am. Surg 1991;57:101-7. 
7. Baron B, Kiproff PM, Khoury MB. Local thrombolysis and 
percutaneous transluminal venoplasty for the venous compli- 
cations of thoracic outlet syndrome: case report. Angiotogy 
1992;43:957-60. 
8. Perler BA, Mitchell SA Percutaneous transluminal ngio- 
plasty and transaxiltarv first rib resection. Am Surg 1986:52: 
485-8. 
9. Urschel HC, Razzuk MA. Improved management of the 
Paget-Schroetter syndrome secondary tothoradc outlet com- 
pression. Ann Thorac Surg 1991:52:1217-21. 
10. Malcynski J, O'Donnell TF, Mackey WC, Millan VA. Long- 
term results oftreatment foraxillary subclavian vein thrombo- 
sis. Can J Surg 1993;36:365-71. 
11. Becker GJ, Holden RW. Mail JT, Olson EW, Castaneda- 
Zmaiga WK Local thrombolytic therapy for "thoracic outlet 
syndrome." Semin Intervent Radiol 1985;2:349-53. 
12. Grassi CJ, Bettmann MA. Effort hrombosis: role ofinterven- 
tional therapy. Cardiovasc Intervent Kadiol 1990;13:3 I7-22. 
13. Elson ID, Becker GJ, Whole,/MH, Ehrman KO. Vena caval 
and central venous tenoses: management with Palmaz bal- 
loon-expandable intralurninal stents. J Vase Intervent Radiol 
1991:2:215-23. 
14 Hall LD, Murray JD, Boswell GE. Venous tent placement as
an adjunct o the staged, multimodal treatment of Paget- 
Schroetter syndrome. J Vase Intervent Radiol 1995;6:565-9. 
15. Inazawa IC Simanuld T, Minowa T, Iijima Y, Orita H, Washio 
M. A case of treatment ofthe Paget-Schroetter syndrome with 
PTA and Gianrureo expandable metal sten~. Nippon Kyobu 
Geka Gakkal Zasshi 1993;41:1410~4. 
16. Wilson JJ, Zahn CA, Newman H. Fibrinolytlc therapy for 
idiopathic subclavian-axillary vein thrombosis. Am J Surg 
1990:159:208-11. 
17. Molina IE. Surgery for effotx thrombosis of the subclavian 
veto. J Thorac Cardiovasc Surg 1992;103:341-6. 
18. Molina JE. Need for emergency treatment insubclavian vein 
effort hrombosis. J Am Coil Surg 1995;181:414-20. 
19. Aziz S, Straehley CJ, Whelan TJ. Effort-related axillosubcla- 
vian vein thrombosis: a new theory ofpathogenesis and a plea 
for direct surgical intervention. Am J Surg 1986;152:57-61. 
20 Machleder HI. Upper extremity venous thrombosis. Semin 
Vasc Surg 1990:3:219-26. 
Submitted May 7, I996: accepted Aug. 17, 1996. 
DISCUSSION 
Dr. Edward M. Druy (Washington, D.C.). One of the 
main points that this paper eally illustrates for us is the role 
of proper patient selection after initial t~ombolysis to try 
to determine what the proper sequencing ofprocedures i  
going to be and which patients are going to really require 
both first-rib resection and stent placement. 
It does not make a great deal of intuitive sense to put a 
stent into a vein as a buttress against mechanical compres- 
sion by the first rib and the subclavius muscle, and I think 
that this was adequately illustrated in the fairly poor results 
that were obtained when our group relied purely on stent 
placement to tt T to maintain patency. 
I think that the key in patient selection and patient 
evaluation is to realize what the status of the collateral 
circulation is like in these patients. I think that it is very, 
important to try to demonstrate the presence or absence of 
collateral vessels because patency can be maintained in  
many of these patients if we can preserve collateral f ow. 
Many of these patients have occlusion ot because their 
veins are occluding, but because their collateral vessels are 
occluding. We do not yet know the physiologic mechanism 
ofcollateral thrombosis, but I think once we find out what 
it is, we will go much further along the way to try to prevent 
rethrombosis in these patients without using any type o~ 
interventional therapy other than the initial thrombolysis. 
A patient who had fairly extensive axiilary-subclavian 
vein thrombosis sought medical attention at our institu~on 
in fairly typical fashion. Twenty-four hours after the initial 
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thrombolytic therapy, there was a lot of residual thrombus 
and compression, and by all criteria one would expect hat 
this vein would thrombose fairly early if no further therapy 
was performed. We did not use further thrombolytic ther- 
apy at this point, we just elected to give him anticoagulation 
therapy, initially with heparin and then with warfarin, for 
about 12 weeks. When we brought him in, we could see 
that all of the residual fibrin strands and residual thrombus 
had lysed, leaving us again with a high-grade stenosis 
without any collateral vessels at all in the neutral view. 
When we stressed the patient, again we could see that 
there was a mild stenosis. There were no collateral vessels in 
the resting view, and the vein obstructed in the stressed 
view. This is the type of patient who probably will have 
rethrombosis without a first-rib resection. I do not believe 
that stent placement has any role in the management of his 
patient because it's purely a mechanical compression oper- 
ating here. 
We had another patient who had extensive thrombosis 
and extensive collateral vessels about the shoulder girdle. 
But after we performed thrombolysis, there was a virtually 
total occlusion at the subclavian-innominate vein junction, 
but very well-developed collateral vessels about hat. This is 
the type of patient who ! do not think would benefit much 
from a first-rib resection. What we needed to do was try to 
maintain collateral flow. The collateral vessels had been 
present for a long time. The patient did something to 
occlude the collateral vessels. We need to determine what 
the effect of certain types of activity are on collateral occlu- 
sion; and if we can prevent that, then I think we can really 
try to prevent these patients from having rethrombosis, as I
said earlier, without performing any other interventional 
procedures. These patients are maintaining flow and main- 
taining function through the use of their collateral vessels. 
I think that until we have a more long-term follow-up 
on the use of stents, particularly in young patients, I 'm 
fairly reluctant o place them either as a primary or a 
secondary form of maintaining patency. We know from 
other patients that 5 or 10 years from now most patients are 
going to develop enough reactive hyperplasia about a stent 
to have rethrombosis or to go on to have restenosis de- 
velop. Until we have a more detailed understanding of the 
mechanism for restenosis, or until we come up with better 
stents that are going to resist restenosis, I think we still need 
to look at alternative strategies for maintaining subclavian 
vein patency after successful initial thrombolysis. 
Dr. George H. Meier. We have some biases of our 
own, I guess. We believe that all of the points that you made 
are completely valid; we do not yet know what these stents 
are going to do. We think that a stent hat is thrombosed 
probably has no worse prognosis for that patient than a vein 
that is thrombosed. We do not think that we are losing 
much by trying to keep these veins open because we really 
believe that occlusion is likely without a stent. We only use 
the stent when there is > 5 0% residual stenosis after balloon 
angioplasty. Unfortunately, that's a very common problem 
in these acute settings. 
I agree that the natural history of acute venous tenoses 
is that some of them will remodel and improve, but none- 
theless we are worried enough about he early rethrombosis 
rate that we would like to try and maintain patency. 
In the short term, at least, stents do not seem to be 
associated with any increase in symptoms or rethrombosis. 
Ore" incidence of rethrombosis appears to be lower than 
that reported by the UCLA group. Long-term follow-up is 
obviously needed. 
Relative to collateral vessels, I think collateral vessels 
form because of restrictions in flow. If you've got a lot of 
collateral vessels, then there probably is some restriction i  
flow and you're going to have some degree of symptoms in 
those patients; the only question ishow much. I would not 
say that I would put as much weight in collateral issues and 
the presence or absence of  collateral vessels as you do. 
There is no question that the absence of Collateral vessels 
bodes poorly for that patient; but by the same token, I think 
that having collateral vessels just tells you there is a prob- 
lem. It doesn't necessarily tell you that the patient is going 
to do well. 
Dr. Michael B. Silva, Jr. (Newark, N.J.). Our under- 
standing of the Palmaz stent is somewhat different han 
yours. One of its specific shortcomings is its deformability, 
which limits its use to locations that do not cross flexion 
points. Is this not why you and your radiology colleagues 
chose to place Wallstents in this position? 
Second, have you seen any migration of the fractured 
Wallstents in follow-up studies, and are you planning any 
additional therapeutic ntervention for those failed proce- 
dures? 
Dr. Meier. In answer to the first question, yes, that is 
exactly why we use the Wallstent, because it is flexible and 
because we do not want to expose the patient o a stent 
deformation, particularly in the period before the first-rib 
resection. 
As for your second question, we assume that once these 
stents fracture that there must be a fair inflammatory e- 
sponse around them and that they are not going to migrate. 
We have not seen any stent migration thus far in any of our 
patients. I think that we are nervous about he outcome of 
these, but we are not willing to prophylactically intervene 
until we know what the natural history of this problem is. 
Rather than putting another stent in to try and salvage the 
situation, we would rather wait and see what the outcome 
is. If thrombosis develops, I think our hope is that we can 
deal with it with thrombolytic therapy and repeat balloon 
dilatation, 
Dr. Dhiraj M. Shah (Albany, N.Y.). I would like to 
congratulate you for bringing up this therapeutic dilemma 
for treatment of Paget-Schrttter disease. Because the 
pathophysiologic mechanism is more of a repeated trauma 
from the thoracic outlet syndrome or compression, as a 
result you have venous channel occlusion or thrombosis. 
Taking care of only the occlusion or the thoracic outlet 
syndrome probably will not take care of the disease as a 
whole; therefore, I think one should think about a treat- 
mcnt strategy that takes care of both problems. We have a 
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protocol that includes immediate thrombolysis, followed 
by first-rib resection and simultaneous stent placement. 
That way, one removes the pathophysiologic mechanism of 
repeated trauma and at the same time removes venous 
thrombosis. In our bands, the protocol produced good 
results, and we suggest hat one should think about ad- 
dressing both offending causes of this disease simulta- 
neously, otherwise failure of one or the other may necessi- 
tate multiple treatments and prolonged recovery. 
Dr. Meier. I assume that you are referring to early 
first-rib resection as opposed to delaying the procedure 3
months? 
Dr. Shah. Yes. It is thrombolysis, first-rib resection. 
followed by stent in the same setting and anticoagulation. 
Dr. Meier. The difficulty for us with early first-rib 
resection is that we believe that we're going to be then 
performing first-rib resection on some patients who are 
inevitably going to have rethrombosis, and to some extent 
we would like to see what the natural history of those 
patients is before we subiect hem to first-rib resection On 
the other hand, I can tell you that half of our first-rib 
resections are done acutely, so it's not that we ignore that 
approach. I think we individualize the treatment and that is 
probably the key. There is no right or wrong answer quite 
yet in this disorder, and I think we're all still trying to find 
our way. I certainly think that early first-rib resection has its 
advocates and has its advantages and disadvantages, a  well. 
Dr. David Calcagno (Camp Hill. Pa.). This is not a 
comment for the Yale group who use Wallstents, but just a 
general comment for the rest of us who are learning from 
each other. I would be very careful about using Palmaz 
stents in the venous circulation, not iust from the crimping 
standpoint, which of course is important, but also remem- 
ber that because the venous ystem gets bigger and bigger 
in the direction of blood flow, the Palmaz stents can float 
away. 
Dr. Meier. When they are used in central veins. Palmaz 
stents have beer. very enthusiastically endorsed, and many 
interventional radiologists uggest hat you can dit~'eren- 
tially dilate the proximal and distal ends and do things that 
are quite creative: but ~ agree with you, I.'m a little nervous 
about them as a whole. 
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